The patient path to a diagnosis of atrial fibrillation (irregular and often abnormally fast heart rate)

Submission date	Recruitment status No longer recruiting	[X] Prospectively registered		
03/11/2022		Protocol		
Registration date	Overall study status Completed	Statistical analysis plan		
15/11/2022		Results		
Last Edited 03/11/2022	Condition category Circulatory System	[] Individual participant data		
		Record updated in last year		

Plain English summary of protocol

Background and study aims

Atrial fibrillation (AF) is a heart condition that causes an irregular heartbeat. It affects up to 10 in 100 people over the age of 65. AF greatly increases the risk of stroke and people with AF are five times more likely to have a stroke compared to people without AF. AF-related strokes are more severe, disabling and fatal than strokes not related to AF. Many people with AF are prescribed medicines known as anticoagulants, which help to reduce blood clots forming and causing an AF-related stroke.

AF can be difficult to detect because the irregular heartbeat is not present at all times and not all patients have symptoms. New research has shown more patients have symptoms than previously thought, and that patients with symptoms experience delay in getting a diagnosis. This is because patients think some of the symptoms are trivial and doctors do not always associate them with AF. Currently, about 500,000 people with AF in England have not been diagnosed. As a result, half of all AF-related strokes occur in people unaware they have AF. Early diagnosis and treatment is vital because patients are at highest risk of stroke in the first four months of having AF.

This study aims to explore patient journeys to AF diagnosis in order to better understand how AF presents. The knowledge from the study will help people to recognise symptoms earlier and seek medical help, and help healthcare professionals to better recognise AF in their day-to-day practice.

Who can participate?

Patients with a recent diagnosis of atrial fibrillation and primary healthcare professionals can participate.

What does the study involve?

The study will be conducted in 20 GP practices in the West Midlands. We will carry out interviews with patients who have received a recent diagnosis of AF to understand the range of symptoms they experienced prior to diagnosis and how AF was detected. We will also carry out interviews

with GPs and practice nurses to understand the challenges of identifying AF in practice. We will then hold a meeting with a small group including patients, AF experts, GPs, practice nurses and individuals from relevant charities to understand the learning from the findings.

Following that, we plan to create educational materials from this learning for the public and healthcare professionals. The findings will be shared with the public, healthcare professionals and the NHS in a number of ways including publications, presentations at conferences for GPs, social media, and posters for display in GP practices. The educational materials will be made widely available on the internet and to all relevant charities and organisations.

The founder of the AF Association who is a member of the research team will lead on sharing findings with the public. Improved public awareness and clinician understanding of AF will result in earlier detection of AF and treatment to reduce AF-related stroke.

What are the possible benefits and risks of participating?

There are no risks in taking part in the study. The knowledge gained from the study may benefit others by helping people to recognise symptoms earlier and seek medical help. The study may also help healthcare professionals to better recognise AF in their day-to-day practice.

Where is the study run from? Institute of Applied Health Research, University of Birmingham (UK)

When is the study starting and how long is it expected to run for? April 2020 to September 2023

Who is funding the study?
NIHR Research for Patient Benefit Programme (UK)

Who is the main contact? Dr Patricia Apenteng, p.n.k.apenteng@bham.ac.uk

Contact information

Type(s)

Principal Investigator

Contact name

Dr Patricia Apenteng

ORCID ID

http://orcid.org/0000-0003-0835-3495

Contact details

Institute of Applied Health Research Murray Learning Centre Birmingham United Kingdom B15 2TT +44 1214148666 p.n.k.apenteng@bham.ac.uk

Additional identifiers

EudraCT/CTIS number

Nil known

IRAS number

317170

ClinicalTrials.gov number

Nil known

Secondary identifying numbers

IRAS 317170. CPMS 53867

Study information

Scientific Title

The Patient Path to a diagnosis of Atrial Fibrillation: a qualitative study in primary care

Acronym

P-PAF

Study objectives

This research seeks to address the patient identification gap in atrial fibrillation through generation of knowledge to improve awareness of the presentations of atrial fibrillation among public and health professionals.

Ethics approval required

Old ethics approval format

Ethics approval(s)

Approved 22/09/2022, East of Scotland Research Ethics Service (Tayside Medical Science Centre, Dundee DD1 9SY, UK; +44(0)1382383878; tay.eosres@nhs.scot), ref: 22/ES/0040

Study design

Qualitative study

Primary study design

Observational

Secondary study design

Qualitative study

Study setting(s)

GP practice

Study type(s)

Other

Participant information sheet

Not available in web format, please use contact details to request a participant information sheet

Health condition(s) or problem(s) studied

Atrial fibrillation

Interventions

Participants will take part in one interview with the study researcher. The interview will last up to one hour.

Intervention Type

Other

Primary outcome measure

- 1. Patient experiences of the journey to diagnosis of atrial fibrillation will be measured using qualitative interviews.
- 2. The perspectives of primary health care professionals on the detection of atrial fibrillation in primary care will be measured using qualitative interviews.

The qualitative data will be analysed using framework analysis, and Andersen's model of Total Patient Delay will be applied as a guide to understand the trajectory to a diagnosis of AF.

Secondary outcome measures

There are no secondary outcome measures

Overall study start date

01/04/2022

Completion date

30/09/2023

Eligibility

Key inclusion criteria

Patients

- 1. Men and women aged 50 years and above
- 2. With a diagnosis of AF within the last 6 months
- 3. Ability to understand the information provided in the participant information sheet and consent form
- 4. Ability to provide informed consent

Primary healthcare professionals

- 1. General practitioners
- 2. Practice nurses
- 3. Ability to provide informed consent

Participant type(s)

Mixed

Age group

Lower age limit

50 Years

Sex

Both

Target number of participants

50

Key exclusion criteria

Patients

- 1. Patients that the GP determines are not suitable to be approached to participate e.g. patients receiving end of life care
- 2. People aged below 50 years
- 3. People who lack capacity to consent

Primary healthcare professionals

1. Participants under 18 years old

Date of first enrolment

01/12/2022

Date of final enrolment

30/06/2023

Locations

Countries of recruitment

England

United Kingdom

Study participating centre University of Birmingham

Institute of Applied Health Research Edgbaston Birmingham United Kingdom B15 2TT

Sponsor information

Organisation

University of Birmingham

Sponsor details

Head of Research Governance and Integrity Finance Office Aston Webb Birmingham England United Kingdom B15 2TT +44 1214147618 researchgovernance@contacts.bham.ac.uk

Sponsor type

University/education

Website

http://www.birmingham.ac.uk/index.aspx

ROR

https://ror.org/03angcq70

Funder(s)

Funder type

Government

Funder Name

National Institute for Health and Care Research

Alternative Name(s)

National Institute for Health Research, NIHR Research, NIHRresearch, NIHR - National Institute for Health Research, NIHR (The National Institute for Health and Care Research), NIHR

Funding Body Type

Government organisation

Funding Body Subtype

National government

Location

United Kingdom

Results and Publications

Publication and dissemination plan

Planned publications in a high-impact peer reviewed journal.

Intention to publish date

31/03/2024

Individual participant data (IPD) sharing plan

The datasets generated during and/or analysed during the current study are not expected to be made available due to participant confidentiality.

IPD sharing plan summary

Not expected to be made available

Study outputs

Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
HRA research summary			28/06/2023	No	No